JP7174428B2 - 救命救急処置の処置における使用のための３－ヒドロキシブチレートの単独または併用 - Google Patents

救命救急処置の処置における使用のための３－ヒドロキシブチレートの単独または併用 Download PDF

Info

Publication number
JP7174428B2
JP7174428B2 JP2019533344A JP2019533344A JP7174428B2 JP 7174428 B2 JP7174428 B2 JP 7174428B2 JP 2019533344 A JP2019533344 A JP 2019533344A JP 2019533344 A JP2019533344 A JP 2019533344A JP 7174428 B2 JP7174428 B2 JP 7174428B2
Authority
JP
Japan
Prior art keywords
composition
hydroxybutyric acid
food
pharmaceutically acceptable
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019533344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502202A5 (enExample
JP2020502202A (ja
Inventor
クロエ ゴーセンス，
リース ラングーシュ，
デン ベルフ， フレート ファン
イルザ ファンホルベーク，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KU Leuven
Original Assignee
KU Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KU Leuven filed Critical KU Leuven
Priority claimed from PCT/EP2017/081394 external-priority patent/WO2018114309A1/en
Publication of JP2020502202A publication Critical patent/JP2020502202A/ja
Publication of JP2020502202A5 publication Critical patent/JP2020502202A5/ja
Application granted granted Critical
Publication of JP7174428B2 publication Critical patent/JP7174428B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019533344A 2016-12-23 2017-12-04 救命救急処置の処置における使用のための３－ヒドロキシブチレートの単独または併用 Active JP7174428B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438771P 2016-12-23 2016-12-23
US62/438,771 2016-12-23
LU100353 2017-08-01
LU100353 2017-08-01
PCT/EP2017/081394 WO2018114309A1 (en) 2016-12-23 2017-12-04 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment

Publications (3)

Publication Number Publication Date
JP2020502202A JP2020502202A (ja) 2020-01-23
JP2020502202A5 JP2020502202A5 (enExample) 2021-01-21
JP7174428B2 true JP7174428B2 (ja) 2022-11-17

Family

ID=60582587

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533344A Active JP7174428B2 (ja) 2016-12-23 2017-12-04 救命救急処置の処置における使用のための３－ヒドロキシブチレートの単独または併用

Country Status (10)

Country Link
US (2) US20190314307A1 (enExample)
EP (1) EP3558291A1 (enExample)
JP (1) JP7174428B2 (enExample)
KR (1) KR20190099469A (enExample)
CN (1) CN110248652B (enExample)
AU (1) AU2017381059B2 (enExample)
BR (1) BR112019012899A2 (enExample)
CA (1) CA3047362A1 (enExample)
CO (1) CO2019007531A2 (enExample)
MX (1) MX390420B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11666548B2 (en) 2020-06-05 2023-06-06 Baxter International Inc. Parenteral nutrition formulation
US20240269096A1 (en) * 2022-12-31 2024-08-15 American Ketone Therapeutics LLC Rapid Onset Therapeutic Ketosis Enabled by D-BetaHydroxyButyric Acid Systems, Compounds and Methods for Sepsis Protection and Enhanced Medical Recovery
CN117243939B (zh) * 2023-11-14 2025-03-07 南京今冉生物新材料科技有限公司 一种酮体缓释物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013150153A1 (en) 2012-04-05 2013-10-10 Tdeltas Limited Ketone bodies and ketone body esters for maintaining or improving muscle power output
WO2015018913A1 (en) 2013-08-07 2015-02-12 Tdeltas Limited Ketone body and ketone body ester for reducing muscle breakdown

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2338090C (en) * 1998-07-22 2009-07-14 Metabolix, Inc. Nutritional and therapeutic compositions of 3-hydroxyacids for increasing blood ketone bodies
CA2339941A1 (en) * 1998-09-15 2000-03-23 Btg International Limited Use of cyclic esters of r-3-hydroxybutyrate for treatment of metabolic and neural degenerative disorders
DK1648952T3 (en) * 2003-06-03 2018-05-28 The Us Gov As Represented By The Department Of Health And Human Services Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives
CN100344280C (zh) * 2005-08-01 2007-10-24 清华大学 3－羟基丁酸及其衍生物的新用途
ES2655367T3 (es) * 2008-08-21 2018-02-19 Oxford University Innovation Limited Bebida que comprende éster de hidroxibutirato y uso médico de la misma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013150153A1 (en) 2012-04-05 2013-10-10 Tdeltas Limited Ketone bodies and ketone body esters for maintaining or improving muscle power output
WO2015018913A1 (en) 2013-08-07 2015-02-12 Tdeltas Limited Ketone body and ketone body ester for reducing muscle breakdown

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CIRCULATION，1987年，75(3)，pp.533-541
Circulatory Shock，1984年，14，pp.63-79
Critical Care Medicine，2000年，28(1)，pp.114-119
Federation Proceedings，1981年，40(3)，p.919
Metabolism，1990年，39(11)，pp.1151-1157
The Journal of Clinical Investigation，1979年，64，pp.1565-1572
The Lancet，2013年，1，pp.621-629

Also Published As

Publication number Publication date
KR20190099469A (ko) 2019-08-27
BR112019012899A2 (pt) 2019-12-03
CN110248652B (zh) 2023-05-26
JP2020502202A (ja) 2020-01-23
US20230310353A1 (en) 2023-10-05
CO2019007531A2 (es) 2020-01-17
MX390420B (es) 2025-03-20
US20190314307A1 (en) 2019-10-17
AU2017381059A1 (en) 2019-07-25
AU2017381059B2 (en) 2023-11-30
MX2019007597A (es) 2019-12-19
NZ755274A (en) 2025-09-26
CA3047362A1 (en) 2018-06-28
US12409159B2 (en) 2025-09-09
EP3558291A1 (en) 2019-10-30
CN110248652A (zh) 2019-09-17

Similar Documents

Publication Publication Date Title
WO2018114309A1 (en) 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment
US12409159B2 (en) 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment
Wilson et al. Effects of beta-hydroxy-beta-methylbutyrate (HMB) on exercise performance and body composition across varying levels of age, sex, and training experience: A review
Tamaki et al. Resveratrol improves oxidative stress and prevents the progression of periodontitis via the activation of the Sirt1/AMPK and the Nrf2/antioxidant defense pathways in a rat periodontitis model
Duvnjak et al. Therapy of nonalcoholic fatty liver disease: current status
Ning et al. Atorvastatin treatment ameliorates cardiac function and remodeling induced by isoproterenol attack through mitigation of ferroptosis
Derde et al. Early parenteral nutrition evokes a phenotype of autophagy deficiency in liver and skeletal muscle of critically ill rabbits
Shannon et al. Dietary nitrate and population health: a narrative review of the translational potential of existing laboratory studies
US20100062090A1 (en) Pharmaceutical Composition Comprising Metadoxine and Garlic Oil For Preventing and Treating Alcohol-Induced Fatty Liver and Steatohepatitis
Brunt et al. Suppression of trimethylamine N-oxide with DMB mitigates vascular dysfunction, exercise intolerance, and frailty associated with a Western-style diet in mice
Peters et al. Dose-dependent effects of leucine supplementation on preservation of muscle mass in cancer cachectic mice
Idrovo et al. Inhibition of lipogenesis reduces inflammation and organ injury in sepsis
NZ575655A (en) Nutrient sensor
JP2010138170A (ja) 抗疲労組成物
Hua et al. Metabolites, gene expression, and gut microbiota profiles suggest the putative mechanisms via which dietary creatine increases the serum taurine and g-ABA contents in Megalobrama amblycephala
Pan et al. Role of Irisin in exercise training-regulated endoplasmic reticulum stress, autophagy and myogenesis in the skeletal muscle after myocardial infarction
KR20080091824A (ko) 메글리티니드류를 함유하는 간 섬유화 예방용 의약 조성물
JP7188936B2 (ja) 抗炎症剤
Deemer et al. Exogenous ketone esters as a potential therapeutic for treatment of sarcopenic obesity
JP2008184429A (ja) 肝臓トリグリセリド濃度低下剤
RU2806867C1 (ru) Средство для профилактики и лечения метаболического синдрома
JP2018127415A (ja) 食後脂質燃焼促進剤
US20120065267A1 (en) Compositions including 3,5-l-t2 and methods of use thereof
Kim et al. Weissella confusa WiKim51 (Wilac D001) fermented mycelium extract attenuates joint inflammation through PGE2 regulation in collagen-induced arthritis rats
Smith et al. Predictors of Clinical Measures of Insulin Resistance: 3542 Board# 230 June 1 9: 30 AM-11: 00 AM

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221028

R150 Certificate of patent or registration of utility model

Ref document number: 7174428

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250